Alzheimer’s Disease – Pipeline Review, H2 2015

“Alzheimer’s Disease – Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Alzheimer’s Disease – Pipeline Review, H2 2015’, provides an overview of the Alzheimer’s Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alzheimer’s Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer’s Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global therapeutic landscape of Alzheimer’s Disease
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Alzheimer’s Disease and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Alzheimer’s Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Alzheimer’s Disease pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products

Reasons to buy

– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Alzheimer’s Disease
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Alzheimer’s Disease pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”

“Table of Contents
Table of Contents 2
Introduction 12
Alzheimer’s Disease Overview 13
Therapeutics Development 14
Alzheimer’s Disease – Therapeutics under Development by Companies 16
Alzheimer’s Disease – Therapeutics under Investigation by Universities/Institutes 35
Alzheimer’s Disease – Pipeline Products Glance 42
Alzheimer’s Disease – Products under Development by Companies 46
Alzheimer’s Disease – Products under Investigation by Universities/Institutes 73
Alzheimer’s Disease – Companies Involved in Therapeutics Development 83
Alzheimer’s Disease – Therapeutics Assessment 285
Drug Profiles 320
Alzheimer’s Disease – Recent Pipeline Updates 980
Alzheimer’s Disease – Dormant Projects 1100
Alzheimer’s Disease – Discontinued Products 1141
Alzheimer’s Disease – Product Development Milestones 1152
Appendix 1159″
“List of Tables
Number of Products under Development for Alzheimer’s Disease, H2 2015 71
Number of Products under Development for Alzheimer’s Disease – Comparative Analysis, H2 2015 72
Number of Products under Development by Companies, H2 2015 74
Number of Products under Development by Companies, H2 2015 (Contd..1) 75
Number of Products under Development by Companies, H2 2015 (Contd..2) 76
Number of Products under Development by Companies, H2 2015 (Contd..3) 77
Number of Products under Development by Companies, H2 2015 (Contd..4) 78
Number of Products under Development by Companies, H2 2015 (Contd..5) 79
Number of Products under Development by Companies, H2 2015 (Contd..6) 80
Number of Products under Development by Companies, H2 2015 (Contd..7) 81
Number of Products under Development by Companies, H2 2015 (Contd..8) 82
Number of Products under Development by Companies, H2 2015 (Contd..9) 83
Number of Products under Development by Companies, H2 2015 (Contd..10) 84
Number of Products under Development by Companies, H2 2015 (Contd..11) 85
Number of Products under Development by Companies, H2 2015 (Contd..12) 86
Number of Products under Development by Companies, H2 2015 (Contd..13) 87
Number of Products under Development by Companies, H2 2015 (Contd..14) 88
Number of Products under Development by Companies, H2 2015 (Contd..15) 89
Number of Products under Development by Companies, H2 2015 (Contd..16) 90
Number of Products under Development by Companies, H2 2015 (Contd..17) 91
Number of Products under Investigation by Universities/Institutes, H2 2015 92
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 93
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 94
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 95
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 96
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..5) 97
Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..6) 98
Comparative Analysis by Late Stage Development, H2 2015 99
Comparative Analysis by Clinical Stage Development, H2 2015 100
Comparative Analysis by Early Stage Development, H2 2015 101
Comparative Analysis by Unknown Stage Development, H2 2015 102
Products under Development by Companies, H2 2015 103
Products under Development by Companies, H2 2015 (Contd..1) 104
Products under Development by Companies, H2 2015 (Contd..2) 105
Products under Development by Companies, H2 2015 (Contd..3) 106
Products under Development by Companies, H2 2015 (Contd..4) 107
Products under Development by Companies, H2 2015 (Contd..5) 108
Products under Development by Companies, H2 2015 (Contd..6) 109
Products under Development by Companies, H2 2015 (Contd..7) 110
Products under Development by Companies, H2 2015 (Contd..8) 111
Products under Development by Companies, H2 2015 (Contd..9) 112
Products under Development by Companies, H2 2015 (Contd..10) 113
Products under Development by Companies, H2 2015 (Contd..11) 114
Products under Development by Companies, H2 2015 (Contd..12) 115
Products under Development by Companies, H2 2015 (Contd..13) 116
Products under Development by Companies, H2 2015 (Contd..14) 117
Products under Development by Companies, H2 2015 (Contd..15) 118
Products under Development by Companies, H2 2015 (Contd..16) 119
Products under Development by Companies, H2 2015 (Contd..17) 120
Products under Development by Companies, H2 2015 (Contd..18) 121
Products under Development by Companies, H2 2015 (Contd..19) 122
Products under Development by Companies, H2 2015 (Contd..20) 123
Products under Development by Companies, H2 2015 (Contd..21) 124
Products under Development by Companies, H2 2015 (Contd..22) 125
Products under Development by Companies, H2 2015 (Contd..23) 126
Products under Development by Companies, H2 2015 (Contd..24) 127
Products under Development by Companies, H2 2015 (Contd..25) 128
Products under Development by Companies, H2 2015 (Contd..26) 129
Products under Investigation by Universities/Institutes, H2 2015 130
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 131
Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 132
Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 133
Products under Investigation by Universities/Institutes, H2 2015 (Contd..4) 134
Products under Investigation by Universities/Institutes, H2 2015 (Contd..5) 135
Products under Investigation by Universities/Institutes, H2 2015 (Contd..6) 136
Products under Investigation by Universities/Institutes, H2 2015 (Contd..7) 137
Products under Investigation by Universities/Institutes, H2 2015 (Contd..8) 138
Products under Investigation by Universities/Institutes, H2 2015 (Contd..9) 139
Alzheimer’s Disease – Pipeline by AB Science SA, H2 2015 140
Alzheimer’s Disease – Pipeline by AbbVie Inc., H2 2015 141
Alzheimer’s Disease – Pipeline by AC Immune SA, H2 2015 142
Alzheimer’s Disease – Pipeline by Acelot, Inc., H2 2015 143
Alzheimer’s Disease – Pipeline by Actinogen Limited, H2 2015 144
Alzheimer’s Disease – Pipeline by Acumen Pharmaceuticals, Inc., H2 2015 145
Alzheimer’s Disease – Pipeline by Addex Therapeutics Ltd, H2 2015 146
Alzheimer’s Disease – Pipeline by Aequus Pharmaceuticals Inc., H2 2015 147
Alzheimer’s Disease – Pipeline by AFFiRiS AG, H2 2015 148
Alzheimer’s Disease – Pipeline by Alector LLC, H2 2015 149
Alzheimer’s Disease – Pipeline by Alkermes Plc, H2 2015 150
Alzheimer’s Disease – Pipeline by ALSP, Inc., H2 2015 151
Alzheimer’s Disease – Pipeline by Alzhyme Pty Ltd, H2 2015 152
Alzheimer’s Disease – Pipeline by Alzinova AB, H2 2015 153
Alzheimer’s Disease – Pipeline by AlzProtect SAS, H2 2015 154
Alzheimer’s Disease – Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015 155
Alzheimer’s Disease – Pipeline by Amgen Inc., H2 2015 156
Alzheimer’s Disease – Pipeline by Anavex Life Sciences Corp., H2 2015 157
Alzheimer’s Disease – Pipeline by Aphios Corporation, H2 2015 158
Alzheimer’s Disease – Pipeline by Apodemus AB, H2 2015 159
Alzheimer’s Disease – Pipeline by Applied Research using OMIC Sciences, S.L., H2 2015 160
Alzheimer’s Disease – Pipeline by Araclon Biotech, S.L., H2 2015 161
Alzheimer’s Disease – Pipeline by Archer Pharmaceuticals, Inc., H2 2015 162
Alzheimer’s Disease – Pipeline by ArmaGen,Inc., H2 2015 163
Alzheimer’s Disease – Pipeline by Artery Therapeutics, Inc., H2 2015 164
Alzheimer’s Disease – Pipeline by AskAt Inc., H2 2015 165
Alzheimer’s Disease – Pipeline by Astellas Pharma Inc., H2 2015 166
Alzheimer’s Disease – Pipeline by AstraZeneca Plc, H2 2015 167
Alzheimer’s Disease – Pipeline by Asubio Pharma Co., Ltd., H2 2015 168
Alzheimer’s Disease – Pipeline by Ausio Pharmaceuticals, LLC, H2 2015 169
Alzheimer’s Disease – Pipeline by Avergen Ltd, H2 2015 170
Alzheimer’s Disease – Pipeline by Avineuro Pharmaceuticals, Inc., H2 2015 171
Alzheimer’s Disease – Pipeline by Axerion Therapeutics, Inc., H2 2015 172
Alzheimer’s Disease – Pipeline by Axon Neuroscience SE, H2 2015 173
Alzheimer’s Disease – Pipeline by Axovant Sciences Ltd., H2 2015 174
Alzheimer’s Disease – Pipeline by Axxam SpA, H2 2015 175
Alzheimer’s Disease – Pipeline by BioArctic Neuroscience AB, H2 2015 176
Alzheimer’s Disease – Pipeline by Bioasis Technologies Inc., H2 2015 177
Alzheimer’s Disease – Pipeline by Biogen, Inc., H2 2015 178
Alzheimer’s Disease – Pipeline by Biomar Microbial Technologies, H2 2015 179
Alzheimer’s Disease – Pipeline by Bionature E.A. Ltd., H2 2015 180
Alzheimer’s Disease – Pipeline by Boehringer Ingelheim GmbH, H2 2015 181
Alzheimer’s Disease – Pipeline by Bristol-Myers Squibb Company, H2 2015 182
Alzheimer’s Disease – Pipeline by Bsim2, H2 2015 183
Alzheimer’s Disease – Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 184
Alzheimer’s Disease – Pipeline by Celon Pharma Sp. z o.o., H2 2015 185
Alzheimer’s Disease – Pipeline by CHA Bio & Diostech Co., Ltd., H2 2015 186
Alzheimer’s Disease – Pipeline by Chase Pharmaceuticals Corporation, H2 2015 187
Alzheimer’s Disease – Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 188
Alzheimer’s Disease – Pipeline by Clera Inc., H2 2015 189
Alzheimer’s Disease – Pipeline by Cognition Therapeutics, Inc., H2 2015 190
Alzheimer’s Disease – Pipeline by Cognosci, Inc., H2 2015 191
Alzheimer’s Disease – Pipeline by CohBar, Inc., H2 2015 192
Alzheimer’s Disease – Pipeline by CoLucid Pharmaceuticals, Inc., H2 2015 193
Alzheimer’s Disease – Pipeline by CoMentis, Inc., H2 2015 194
Alzheimer’s Disease – Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2015 195
Alzheimer’s Disease – Pipeline by Corium International, Inc., H2 2015 196
Alzheimer’s Disease – Pipeline by Cortica Neurosciences, Inc., H2 2015 197
Alzheimer’s Disease – Pipeline by Critical Outcome Technologies Inc., H2 2015 198
Alzheimer’s Disease – Pipeline by Crossbeta Biosciences B.V., H2 2015 199
Alzheimer’s Disease – Pipeline by D-Pharm Ltd., H2 2015 200
Alzheimer’s Disease – Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015 201
Alzheimer’s Disease – Pipeline by Daval International Limited, H2 2015 202
Alzheimer’s Disease – Pipeline by DermaXon, LLC, H2 2015 203
Alzheimer’s Disease – Pipeline by Domain Therapeutics SA, H2 2015 204
Alzheimer’s Disease – Pipeline by Eisai Co., Ltd., H2 2015 205
Alzheimer’s Disease – Pipeline by Eli Lilly and Company, H2 2015 206
Alzheimer’s Disease – Pipeline by EncephRx, Inc., H2 2015 207
Alzheimer’s Disease – Pipeline by ENKAM Pharmaceuticals A/S, H2 2015 208
Alzheimer’s Disease – Pipeline by Ensemble Therapeutics Corporation, H2 2015 209
Alzheimer’s Disease – Pipeline by Epigen Biosciences, Inc., H2 2015 210
Alzheimer’s Disease – Pipeline by Euroscreen S.A., H2 2015 211
Alzheimer’s Disease – Pipeline by Evotec AG, H2 2015 212
Alzheimer’s Disease – Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 213
Alzheimer’s Disease – Pipeline by FORUM Pharmaceuticals Inc., H2 2015 214
Alzheimer’s Disease – Pipeline by Galantos Pharma GmbH (Inactive), H2 2015 215
Alzheimer’s Disease – Pipeline by Genentech, Inc., H2 2015 216
Alzheimer’s Disease – Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015 217
Alzheimer’s Disease – Pipeline by GlaxoSmithKline Plc, H2 2015 218
Alzheimer’s Disease – Pipeline by GliaCure Inc., H2 2015 219
Alzheimer’s Disease – Pipeline by Golden Biotechnology Corp., H2 2015 220
Alzheimer’s Disease – Pipeline by Grifols, S.A., H2 2015 221
Alzheimer’s Disease – Pipeline by H. Lundbeck A/S, H2 2015 222
Alzheimer’s Disease – Pipeline by Heptares Therapeutics Limited, H2 2015 223
Alzheimer’s Disease – Pipeline by Herantis Pharma Plc, H2 2015 224
Alzheimer’s Disease – Pipeline by Humanetics Corporation, H2 2015 225
Alzheimer’s Disease – Pipeline by Ichor Medical Systems, Inc., H2 2015 226
Alzheimer’s Disease – Pipeline by Icure Pharmaceutical Inc., H2 2015 227
Alzheimer’s Disease – Pipeline by IMMD Inc., H2 2015 228
Alzheimer’s Disease – Pipeline by Immunome Inc., H2 2015 229
Alzheimer’s Disease – Pipeline by Impel NeuroPharma, Inc., H2 2015 230
Alzheimer’s Disease – Pipeline by ImStar Therapeutics Inc., H2 2015 231
Alzheimer’s Disease – Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 232
Alzheimer’s Disease – Pipeline by Intellect Neurosciences, Inc., H2 2015 233
Alzheimer’s Disease – Pipeline by Intra-Cellular Therapies, Inc., H2 2015 234
Alzheimer’s Disease – Pipeline by Io Therapeutics, Inc., H2 2015 235
Alzheimer’s Disease – Pipeline by Iproteos S.L., H2 2015 236
Alzheimer’s Disease – Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 237
Alzheimer’s Disease – Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2015 238
Alzheimer’s Disease – Pipeline by Johnson & Johnson, H2 2015 239
Alzheimer’s Disease – Pipeline by K-Stemcell Co., Ltd., H2 2015 240
Alzheimer’s Disease – Pipeline by Kadmon Corporation, LLC, H2 2015 241
Alzheimer’s Disease – Pipeline by Kalgene Pharmaceuticals Inc., H2 2015 242
Alzheimer’s Disease – Pipeline by Kareus Therapeutics, SA, H2 2015 243
Alzheimer’s Disease – Pipeline by KineMed, Inc., H2 2015 244
Alzheimer’s Disease – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 245
Alzheimer’s Disease – Pipeline by Lead Discovery Center GmbH, H2 2015 246
Alzheimer’s Disease – Pipeline by Les Laboratoires Servier SAS, H2 2015 247
Alzheimer’s Disease – Pipeline by Lipopharma Therapeutics SL, H2 2015 248
Alzheimer’s Disease – Pipeline by Living Cell Technologies Limited, H2 2015 249
Alzheimer’s Disease – Pipeline by Lupin Limited, H2 2015 250
Alzheimer’s Disease – Pipeline by ManRos Therapeutics, H2 2015 251
Alzheimer’s Disease – Pipeline by MedDay, H2 2015 252
Alzheimer’s Disease – Pipeline by Medestea Research & Production S.p.A., H2 2015 253
Alzheimer’s Disease – Pipeline by MedImmune, LLC, H2 2015 254
Alzheimer’s Disease – Pipeline by Medisyn Technologies, Inc., H2 2015 255
Alzheimer’s Disease – Pipeline by Merck & Co., Inc., H2 2015 256
Alzheimer’s Disease – Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015 257
Alzheimer’s Disease – Pipeline by Metabolic Solutions Development Company, LLC, H2 2015 258
Alzheimer’s Disease – Pipeline by Mithridion, Inc., H2 2015 259
Alzheimer’s Disease – Pipeline by NAL Pharmaceuticals Ltd., H2 2015 260
Alzheimer’s Disease – Pipeline by Nanomerics Ltd, H2 2015 261
Alzheimer’s Disease – Pipeline by Nanotherapeutics, Inc., H2 2015 262
Alzheimer’s Disease – Pipeline by Neuralstem, Inc., H2 2015 263
Alzheimer’s Disease – Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015 264
Alzheimer’s Disease – Pipeline by Neurim Pharmaceuticals Ltd, H2 2015 265
Alzheimer’s Disease – Pipeline by Neurodyn Inc., H2 2015 266
Alzheimer’s Disease – Pipeline by NeuroGenetic Pharmaceuticals, Inc., H2 2015 267
Alzheimer’s Disease – Pipeline by NeuroNascent, Inc., H2 2015 268
Alzheimer’s Disease – Pipeline by Neuronax SAS, H2 2015 269
Alzheimer’s Disease – Pipeline by NeurOp, Inc, H2 2015 270
Alzheimer’s Disease – Pipeline by Neuropore Therapies, Inc., H2 2015 271
Alzheimer’s Disease – Pipeline by Neurotez, Inc., H2 2015 272
Alzheimer’s Disease – Pipeline by New World Laboratories, Inc., H2 2015 273
Alzheimer’s Disease – Pipeline by nLife Therapeutics, S.L., H2 2015 274
Alzheimer’s Disease – Pipeline by Novartis AG, H2 2015 275
Alzheimer’s Disease – Pipeline by Oligomerix, inc., H2 2015 276
Alzheimer’s Disease – Pipeline by Oryzon Genomics S.A., H2 2015 277
Alzheimer’s Disease – Pipeline by P2D Bioscience, H2 2015 278
Alzheimer’s Disease – Pipeline by Pain Therapeutics, Inc., H2 2015 279
Alzheimer’s Disease – Pipeline by Palumed S.A., H2 2015 280
Alzheimer’s Disease – Pipeline by Panacea Pharmaceuticals, Inc., H2 2015 281
Alzheimer’s Disease – Pipeline by PeptiDream Inc., H2 2015 282
Alzheimer’s Disease – Pipeline by Peptron, Inc., H2 2015 283
Alzheimer’s Disease – Pipeline by Pfizer Inc., H2 2015 284
Alzheimer’s Disease – Pipeline by PharmaKure Limited, H2 2015 285
Alzheimer’s Disease – Pipeline by PharmatrophiX, Inc., H2 2015 286
Alzheimer’s Disease – Pipeline by Pharnext SAS, H2 2015 287
Alzheimer’s Disease – Pipeline by Phenomenome Discoveries, Inc., H2 2015 288
Alzheimer’s Disease – Pipeline by PhysioGenix, Inc., H2 2015 289
Alzheimer’s Disease – Pipeline by Pivot Pharmaceuticals Inc, H2 2015 290
Alzheimer’s Disease – Pipeline by Plexxikon Inc., H2 2015 291
Alzheimer’s Disease – Pipeline by Prana Biotechnology Limited, H2 2015 292
Alzheimer’s Disease – Pipeline by Probiodrug AG, H2 2015 293
Alzheimer’s Disease – Pipeline by Progenra, Inc., H2 2015 294
Alzheimer’s Disease – Pipeline by Proteome Sciences Plc, H2 2015 295
Alzheimer’s Disease – Pipeline by Proteostasis Therapeutics, Inc., H2 2015 296
Alzheimer’s Disease – Pipeline by ProteoTech, Inc., H2 2015 297
Alzheimer’s Disease – Pipeline by Prothena Corporation Plc, H2 2015 298
Alzheimer’s Disease – Pipeline by QR Pharma, Inc., H2 2015 299
Alzheimer’s Disease – Pipeline by Radius Health, Inc., H2 2015 300
Alzheimer’s Disease – Pipeline by Regenera Pharma Ltd., H2 2015 301
Alzheimer’s Disease – Pipeline by reMYND NV, H2 2015 302
Alzheimer’s Disease – Pipeline by Resverlogix Corp., H2 2015 303
Alzheimer’s Disease – Pipeline by Sage Therapeutics, H2 2015 304
Alzheimer’s Disease – Pipeline by SanBio, Inc., H2 2015 305
Alzheimer’s Disease – Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015 306
Alzheimer’s Disease – Pipeline by Saniona AB, H2 2015 307
Alzheimer’s Disease – Pipeline by Sanofi, H2 2015 308
Alzheimer’s Disease – Pipeline by Selvita SA, H2 2015 309
Alzheimer’s Disease – Pipeline by SeneXta Therapeutics SA, H2 2015 310
Alzheimer’s Disease – Pipeline by Serometrix, LLC, H2 2015 311
Alzheimer’s Disease – Pipeline by Siena Biotech S.p.A., H2 2015 312
Alzheimer’s Disease – Pipeline by SignPath Pharma Inc, H2 2015 313
Alzheimer’s Disease – Pipeline by Simcere Pharmaceutical Group, H2 2015 314
Alzheimer’s Disease – Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 315
Alzheimer’s Disease – Pipeline by SOM Innovation Biotech SL, H2 2015 316
Alzheimer’s Disease – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015 317
Alzheimer’s Disease – Pipeline by Stemedica Cell Technologies, Inc., H2 2015 318
Alzheimer’s Disease – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015 319
Alzheimer’s Disease – Pipeline by Summit Therapeutics Plc, H2 2015 320
Alzheimer’s Disease – Pipeline by Suven Life Sciences Ltd., H2 2015 321
Alzheimer’s Disease – Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 322
Alzheimer’s Disease – Pipeline by TauRx Therapeutics Ltd., H2 2015 323
Alzheimer’s Disease – Pipeline by Tautatis Incorporated, H2 2015 324
Alzheimer’s Disease – Pipeline by TechnologieAllianz e. V., H2 2015 325
Alzheimer’s Disease – Pipeline by TechnoPhage SA, H2 2015 326
Alzheimer’s Disease – Pipeline by Tetra Discovery Partners LLC, H2 2015 327
Alzheimer’s Disease – Pipeline by Therapix Biosciences Ltd, H2 2015 328
Alzheimer’s Disease – Pipeline by Toyama Chemical Co., Ltd., H2 2015 329
Alzheimer’s Disease – Pipeline by Transition Therapeutics Inc., H2 2015 330
Alzheimer’s Disease – Pipeline by Treventis Corporation, H2 2015 331
Alzheimer’s Disease – Pipeline by TyrNovo Ltd., H2 2015 332
Alzheimer’s Disease – Pipeline by UCB S.A., H2 2015 333
Alzheimer’s Disease – Pipeline by Varinel, Inc., H2 2015 334
Alzheimer’s Disease – Pipeline by Virobay Inc., H2 2015 335
Alzheimer’s Disease – Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 336
Alzheimer’s Disease – Pipeline by Vivus, Inc., H2 2015 337
Alzheimer’s Disease – Pipeline by vTv Therapeutics LLC, H2 2015 338
Alzheimer’s Disease – Pipeline by Vybion, Inc., H2 2015 339
Alzheimer’s Disease – Pipeline by Wellstat Therapeutics Corporation, H2 2015 340
Alzheimer’s Disease – Pipeline by Zenobia Therapeutics, Inc., H2 2015 341
Assessment by Monotherapy Products, H2 2015 342
Assessment by Combination Products, H2 2015 343
Number of Products by Stage and Target, H2 2015 345
Number of Products by Stage and Mechanism of Action, H2 2015 362
Number of Products by Stage and Route of Administration, H2 2015 374
Number of Products by Stage and Molecule Type, H2 2015 376
Alzheimer’s Disease Therapeutics – Recent Pipeline Updates, H2 2015 1037
Alzheimer’s Disease – Dormant Projects, H2 2015 1157
Alzheimer’s Disease – Dormant Projects (Contd..1), H2 2015 1158
Alzheimer’s Disease – Dormant Projects (Contd..2), H2 2015 1159
Alzheimer’s Disease – Dormant Projects (Contd..3), H2 2015 1160
Alzheimer’s Disease – Dormant Projects (Contd..4), H2 2015 1161
Alzheimer’s Disease – Dormant Projects (Contd..5), H2 2015 1162
Alzheimer’s Disease – Dormant Projects (Contd..6), H2 2015 1163
Alzheimer’s Disease – Dormant Projects (Contd..7), H2 2015 1164
Alzheimer’s Disease – Dormant Projects (Contd..8), H2 2015 1165
Alzheimer’s Disease – Dormant Projects (Contd..9), H2 2015 1166
Alzheimer’s Disease – Dormant Projects (Contd..10), H2 2015 1167
Alzheimer’s Disease – Dormant Projects (Contd..11), H2 2015 1168
Alzheimer’s Disease – Dormant Projects (Contd..12), H2 2015 1169
Alzheimer’s Disease – Dormant Projects (Contd..13), H2 2015 1170
Alzheimer’s Disease – Dormant Projects (Contd..14), H2 2015 1171
Alzheimer’s Disease – Dormant Projects (Contd..15), H2 2015 1172
Alzheimer’s Disease – Dormant Projects (Contd..16), H2 2015 1173
Alzheimer’s Disease – Dormant Projects (Contd..17), H2 2015 1174
Alzheimer’s Disease – Dormant Projects (Contd..18), H2 2015 1175
Alzheimer’s Disease – Dormant Projects (Contd..19), H2 2015 1176
Alzheimer’s Disease – Dormant Projects (Contd..20), H2 2015 1177
Alzheimer’s Disease – Dormant Projects (Contd..21), H2 2015 1178
Alzheimer’s Disease – Dormant Projects (Contd..22), H2 2015 1179
Alzheimer’s Disease – Dormant Projects (Contd..23), H2 2015 1180
Alzheimer’s Disease – Dormant Projects (Contd..24), H2 2015 1181
Alzheimer’s Disease – Dormant Projects (Contd..25), H2 2015 1182
Alzheimer’s Disease – Dormant Projects (Contd..26), H2 2015 1183
Alzheimer’s Disease – Dormant Projects (Contd..27), H2 2015 1184
Alzheimer’s Disease – Dormant Projects (Contd..28), H2 2015 1185
Alzheimer’s Disease – Dormant Projects (Contd..29), H2 2015 1186
Alzheimer’s Disease – Dormant Projects (Contd..30), H2 2015 1187
Alzheimer’s Disease – Dormant Projects (Contd..31), H2 2015 1188
Alzheimer’s Disease – Dormant Projects (Contd..32), H2 2015 1189
Alzheimer’s Disease – Dormant Projects (Contd..33), H2 2015 1190
Alzheimer’s Disease – Dormant Projects (Contd..34), H2 2015 1191
Alzheimer’s Disease – Dormant Projects (Contd..35), H2 2015 1192
Alzheimer’s Disease – Dormant Projects (Contd..36), H2 2015 1193
Alzheimer’s Disease – Dormant Projects (Contd..37), H2 2015 1194
Alzheimer’s Disease – Dormant Projects (Contd..38), H2 2015 1195
Alzheimer’s Disease – Dormant Projects (Contd..39), H2 2015 1196
Alzheimer’s Disease – Dormant Projects (Contd..40), H2 2015 1197
Alzheimer’s Disease – Discontinued Products, H2 2015 1198
Alzheimer’s Disease – Discontinued Products (Contd..1), H2 2015 1199
Alzheimer’s Disease – Discontinued Products (Contd..2), H2 2015 1200
Alzheimer’s Disease – Discontinued Products (Contd..3), H2 2015 1201
Alzheimer’s Disease – Discontinued Products (Contd..4), H2 2015 1202
Alzheimer’s Disease – Discontinued Products (Contd..5), H2 2015 1203
Alzheimer’s Disease – Discontinued Products (Contd..6), H2 2015 1204
Alzheimer’s Disease – Discontinued Products (Contd..7), H2 2015 1205
Alzheimer’s Disease – Discontinued Products (Contd..8), H2 2015 1206
Alzheimer’s Disease – Discontinued Products (Contd..9), H2 2015 1207
Alzheimer’s Disease – Discontinued Products (Contd..10), H2 2015 1208″
“List of Figures
Number of Products under Development for Alzheimer’s Disease, H2 2015 71
Number of Products under Development for Alzheimer’s Disease – Comparative Analysis, H2 2015 72
Number of Products under Development by Companies, H2 2015 73
Number of Products under Investigation by Universities/Institutes, H2 2015 92
Comparative Analysis by Late Stage Development, H2 2015 99
Comparative Analysis by Clinical Stage Development, H2 2015 100
Comparative Analysis by Early Stage Products, H2 2015 101
Assessment by Monotherapy Products, H2 2015 342
Assessment by Combination Products, H2 2015 343
Number of Products by Top 10 Targets, H2 2015 344
Number of Products by Stage and Top 10 Targets, H2 2015 344
Number of Products by Top 10 Mechanism of Actions, H2 2015 361
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 361
Number of Products by Top 10 Routes of Administration, H2 2015 373
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 373
Number of Products by Top 10 Molecule Types, H2 2015 375
Number of Products by Stage and Top 10 Molecule Types, H2 2015 375″